Skip to main content
Top
Published in: Journal of Gastroenterology 3/2010

01-03-2010 | Letter to the Editor

Can an incomplete stent expansion modulate the effects of TIPS?

Authors: Oliviero Riggio, Stefania Angeloni, Lorenzo Ridola, Plinio Rossi

Published in: Journal of Gastroenterology | Issue 3/2010

Login to get access

Excerpt

We found the paper entitled TIPS for refractory ascites: a single center experience by Thalheimer et al. [1] to be of great interest, since it reports the retrospective analysis of their results obtained in patients with refractory ascites submitted to transjugular intrahepatic portosystemic shunt (TIPS) according to a protocol in which the stent used to construct the shunt was not completely expanded. The authors suggest that an incomplete stent expansion may reduce the occurrence of hepatic encephalopathy by also maintaining the efficacy of the shunt in terms of resolution of ascites. However, to test such a hypothesis, a randomized controlled trial comparing a limited versus a complete stent expansion should have been carried out. This was not the case, and, considering that the paper is a pilot study, we have some doubts regarding the methodology used and the possibility that a limited stent expansion can be useful in patients who need a TIPS. The portal pressure gradient (PPG) value that should be achieved after the stent expansion to solve the ascites and the PPG value that can avoid the occurrence of encephalopathy are in fact both unknown. It is therefore difficult to understand why the authors decided to stop the stent dilatation when the PPG reduction was more than 25%. Furthermore, we do not believe that the PPG value measured immediately after TIPS opening remains stable over time. Immediately after the procedure, in fact, the amount of blood reaching the heart increases rapidly, and a rise in the right atrium and the central venous pressure has already been described [2]. This value does not remain stable over time [3, 4]; it is therefore possible that a reduction of 25% in the PPG value measured immediately after TIPS may not be the same a few days or weeks later. We therefore wonder whether the authors have some evidence that the PPG value reached immediately after TIPS opening had remained stable over time. …
Literature
1.
go back to reference Thalheimer U, Leandro G, Samanakis DN, Triantos CK, Senzolo M, Fung K, et al. TIPS for refractory ascites: a single center experience. J Gastroenterol. 2009;44:1089–95.CrossRefPubMed Thalheimer U, Leandro G, Samanakis DN, Triantos CK, Senzolo M, Fung K, et al. TIPS for refractory ascites: a single center experience. J Gastroenterol. 2009;44:1089–95.CrossRefPubMed
2.
go back to reference Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol. 2002;97:142–8.CrossRefPubMed Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol. 2002;97:142–8.CrossRefPubMed
3.
go back to reference Lotterer E, Wengert A, Fleig WE. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology. 1999;29:632–9.CrossRefPubMed Lotterer E, Wengert A, Fleig WE. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology. 1999;29:632–9.CrossRefPubMed
4.
go back to reference Colombato LA, Spahr L, Martinet JP, Dufresne MP, Lafortune M, Fenyves D, et al. Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients. Gut. 1996;39:600–4.CrossRefPubMed Colombato LA, Spahr L, Martinet JP, Dufresne MP, Lafortune M, Fenyves D, et al. Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients. Gut. 1996;39:600–4.CrossRefPubMed
5.
go back to reference Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004;126:469–75.CrossRefPubMed Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004;126:469–75.CrossRefPubMed
6.
go back to reference Angeloni S, Merli M, Salvatori F, et al. Polytetrafluorethylene-covered stent-graft for TIPS procedure: 1-year patency and clinical results. Am J Gastroenterol. 2004;99:280–5.CrossRefPubMed Angeloni S, Merli M, Salvatori F, et al. Polytetrafluorethylene-covered stent-graft for TIPS procedure: 1-year patency and clinical results. Am J Gastroenterol. 2004;99:280–5.CrossRefPubMed
Metadata
Title
Can an incomplete stent expansion modulate the effects of TIPS?
Authors
Oliviero Riggio
Stefania Angeloni
Lorenzo Ridola
Plinio Rossi
Publication date
01-03-2010
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 3/2010
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-009-0175-y

Other articles of this Issue 3/2010

Journal of Gastroenterology 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.